For primary hyperlipidemia. ANDA 205961, held by Amneal Pharms Ny. Pitavastatin Calcium.
As of Nov 16, 2026, ANDA 205961 (Pitavastatin Calcium), held by Amneal Pharms Ny, was first approved by FDA on Aug 20, 2024, with 0 approved supplements and 0 published complete response letters.
Pitavastatin tablets are indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in: Adults with primary hyperlipidemia. Adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 20, 2024 | Original application | Approved |
| Pitavastatin CalciumEQ 1MG BASE · tablet;oral | Pitavastatin Calcium | Rx |
| Pitavastatin CalciumEQ 2MG BASE · tablet;oral | Pitavastatin Calcium | Rx |
| Pitavastatin CalciumEQ 4MG BASE · tablet;oral | Pitavastatin Calcium | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters